JPM23: Vaccine developers as dealmakers, Gilead’s trial tea leaves and building platform companies

Even so, more breathing room hasn’t stemmed the flow of news. JPM has historically been a sought-after venue for companies to kick off the year with a big announcement or deal. Sunday and Monday brought three of the latter, even if all were of the smaller variety.

Analysts kept the deal talks going by asking what many investors have been wondering. What are companies Pfizer and Moderna, flush with cash from COVID-19 vaccines and treatments, going to buy with all that money?